An open-label, phase Ib, dose-escalation study of the safety and pharmacology of the anti-CD40 monoclonal antibody SGN-40 administered in combination with bortezomib (Velcade, PS-341) in patients with relapsed or refractory multiple myeloma.

Trial Profile

An open-label, phase Ib, dose-escalation study of the safety and pharmacology of the anti-CD40 monoclonal antibody SGN-40 administered in combination with bortezomib (Velcade, PS-341) in patients with relapsed or refractory multiple myeloma.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2014

At a glance

  • Drugs Dacetuzumab (Primary) ; Bortezomib
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 14 Nov 2011 Actual end date Apr 2010 added as reported by ClinicalTrials.gov.
    • 31 Mar 2010 Actual patient number (18) added as reported by ClinicalTrials.gov.
    • 31 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top